This presentation provides an overview of xylazine, current data on prevalence and other trends.
Our speaker is Michael Chaple, PhD, Assistant Professor of Clinical Psychiatry at Columbia University Irving Medical Center, and Director of the Northeast and Caribbean Rural Opioid Technical Assistance Center. This presentation provides an overview of xylazine, current data on prevalence and other trends associated with its use, and also discusses the public health implications associated with xylazine use. This presentation offers harm reduction strategies for mitigating the public health impact of xylazine. Throughout the presentation, unique implications for rural communities are systematically addressed.
Learning objectives:
1. Describe xylazine and its inclusion as an adulterant in the drug supply
2. Discuss the public health impact of xylazine use (i.e., development of wounds, impact on overdose and overdose response, clinical implications for treatment)
3. Outline other harm reduction techniques that can address xylazine use
4. Discuss how xylazine impacts members of rural communities